Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Net Shares Issued and Repurchased (2010 - 2016)

Grifols' (GRFS) quarterly Net Shares Issued and Repurchased came in at $12.7 million in Q4 2016, up 191.3% YoY from $4.4 million in Q1 2016, and up 271.37% on a QoQ basis from -$7.4 million in Q3 2016.

Grifols (GRFS) Net Shares Issued and Repurchased (2010 - 2016) Analysis & Trends

Grifols (GRFS) has 7 years of Net Shares Issued and Repurchased data on file, last reported at $12.7 million in Q4 2016.

  • Quarterly Net Shares Issued and Repurchased rose 191.3% year-over-year to $12.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$8.6 million (up 53.87% YoY) and the FY2021 annual result came in at -$143.8 million, changed N/A from the prior year.
  • Net Shares Issued and Repurchased grew to $12.7 million in Q4 2016, from -$7.4 million in the prior quarter.
  • In the past five years, Net Shares Issued and Repurchased ranged from a high of $220.2 million in Q2 2013 to a low of -$110.0 million in Q1 2013.
  • A 5-year average of $2.6 million and a median of -$60856.2 in 2014 frame the typical range for Net Shares Issued and Repurchased.
  • Annual changes were most pronounced in 2013 — Net Shares Issued and Repurchased slumped 4193096.4% — and 2014, when it jumped 212.22%.
  • Tracing GRFS's Net Shares Issued and Repurchased over 5 years: stood at -$14265.8 in 2012, then plunged by 478157.35% to -$68.2 million in 2013, then jumped by 212.22% to $76.6 million in 2014, then plunged by 118.16% to -$13.9 million in 2015, then surged by 191.3% to $12.7 million in 2016.
  • The last three Net Shares Issued and Repurchased figures came in at $12.7 million (Q4 2016), -$7.4 million (Q3 2016), and -$13.9 million (Q4 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Shares Issued and Repurchased (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2016 12.69 Mn
Dec 31, 2016 12.69 Mn
Sep 30, 2016 -7.41 Mn
Sep 30, 2016 -7.41 Mn
Dec 31, 2015 -13.90 Mn
Dec 31, 2015 -13.90 Mn
Dec 31, 2014 76.56 Mn
Dec 31, 2014 76.56 Mn
Sep 30, 2014 -81.34 Mn
Sep 30, 2014 -81.34 Mn
Jun 30, 2014 -60,856.23
Jun 30, 2014 -60,856.23
Dec 31, 2013 -68.23 Mn
Dec 31, 2013 -68.23 Mn
Jun 30, 2013 220.19 Mn
Jun 30, 2013 220.19 Mn
Mar 31, 2013 -109.97 Mn
Mar 31, 2013 -109.97 Mn
Dec 31, 2012 -14,265.82
Dec 31, 2012 -14,265.82